Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a ...
Antennova presented ATN-037 data at ESMO Congress 2024, showing ORR of 21.1% and DCR of 89.5% in NSCLC/melanoma patients resistant to CPIs. Phase I data indicated ATN-037's potential to reverse anti-PD-1 resistance.
Reference News
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a ...
Antennova presented ATN-037 data at ESMO Congress 2024, showing ORR of 21.1% and DCR of 89.5% in NSCLC/melanoma patients resistant to CPIs. Phase I data indicated ATN-037's potential to reverse anti-PD-1 resistance.